Mandate

Vinge has advised Azelio in connection with a directed share issue of SEK 270 million

September 10, 2020 Capital Markets and Public M&A

Vinge has advised Azelio, a public Swedish company specialising in thermal energy storage with dispatchable and low-cost Stirling-based electricity and heat production, in connection with a directed share issue whereby Azelio raises SEK 270 million in issue proceeds before transaction costs.

The subscription price was determined to SEK 22 per share through a so called accelerated bookbuilding procedure. The share issue was directed to a number of Swedish and international institutional investors. The main purpose of the share issue is to finance the company’s ongoing operations and the continued industrialization of Azelio’s Thermal Energy Storage (TES) and Stirling-based electricity production technology, with the objective of reaching industrial volume production in 2021. Azelio’s shares are listed on Nasdaq First North Growth Market.

Vinge’s team consisted of David Andersson, William Kåge, Julia Hirschberg and Olof Löfvenberg.

Related

Vinge advises Atria Sverige in conjunction with an investment in Cookin Food

Atria Sverige has acquired a 25 per cent stake in the Swedish convenience food company Cookin Food Sweden AB. The transaction has been performed through the acquisition of shares in Bite Delight AB, which owns Cookin Food Sweden AB. Atria holds an option to acquire the remaining shares in Bite Delight AB after 2028.
March 04, 2026

Vinge advises Revivo Group on the acquisition of Solidenergy

Revivo Group, a portfolio company of Helix Kapital, has acquired Solidenergy, a leading provider of surface treatment services in the Norwegian market. The company operates within the energy, offshore and infrastructure sectors and is headquartered in Ågotnes outside Bergen. Solidenergy employs approximately 600 people.
March 03, 2026

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a partially guaranteed rights issue which is expected to provide Oncopeptides with proceeds of approximately SEK 200 million before deduction of transaction costs.
March 03, 2026